Skip to main content
OpenTrials
Completed

NCT Number: NCT06656039

A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

The main goal of this observational study is to construct a predictive recurrence model for renal clear cell carcinoma through an artificial intelligence multimodal algorithm, which will improve the prognosis and survival time of ccRCC patients by helping clinicians to formulate individualised follow-up and to screen for appropriate adjuvant therapy candidates.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma, Clear Cell Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Renji Hospital

Shanghai, Shanghai Municipality, 200120, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with malignant renal tumours must have postoperative pathological confirmation of renal clear cell carcinoma with pathological TNM stage Ⅰ-Ⅲ;
  • Have available preoperative imaging
  • Have available post-operative pathological paraffin samples or HE-stained tissue sections
  • Must agree to and be able to comply with the study's visit schedule and other requirements as specified in the protocol, including follow-up visits by telephone

Exclusion criteria

  • The patient's tumour type cannot be determined on the basis of histopathological sections
  • Simultaneous combination of primary tumours at other sites;
  • No regular follow-up imaging data
  • Cases in which other factors led the investigator to believe that enrolment was inappropriate
  • Cases that met all the inclusion criteria of the appeal and did not meet all the exclusion criteria were selected for this study

Treatment and study plan

Primary outcomes

  1. Disease free survival

    Time frame: "Baseline, immediately after the surgery", "Tumour recurrence or further follow-up", "Three months after surgery", "Six months after surgery", "Every year after surgery, at least follow-up 2years, up to 10 years"

    Defined as from surgery to tumor recurrence or follow-up deadline

Sponsors and collaborators

Lead sponsor

RenJi Hospital

Other

Collaborators

  • Chang Gung Memorial Hospital
  • Qianfoshan Hospital
  • Second Affiliated Hospital of Soochow University
  • The First Affiliated Hospital of Anhui Medical University
  • The Fourth Affiliated Hospital of Harbin Medical University

Registry information

Official study title

Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Oct 24, 2024
Registry last updated
Oct 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.